Juno Therapeutics Inc (NASDAQ:JUNO) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,637,584 shares, a drop of 58.8% from the January 12th total of 8,834,492 shares. Based on an average trading volume of 10,485,500 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.3% of the shares of the company are sold short.
In related news, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $391,650.00. Following the sale, the chief financial officer now directly owns 772,082 shares in the company, valued at approximately $34,558,390.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Robert Azelby sold 3,497 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $85.77, for a total value of $299,937.69. Following the completion of the sale, the executive vice president now owns 93,771 shares in the company, valued at $8,042,738.67. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 468,874 shares of company stock worth $26,675,574. 15.08% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of JUNO. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares during the last quarter. Advisor Group Inc. grew its holdings in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares during the last quarter. QS Investors LLC acquired a new position in shares of Juno Therapeutics in the 2nd quarter worth $135,000. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 3,559 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in shares of Juno Therapeutics in the 4th quarter worth $173,000. Institutional investors and hedge funds own 69.13% of the company’s stock.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company’s quarterly revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.57) EPS. analysts anticipate that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.
Several analysts recently commented on the company. Raymond James Financial cut Juno Therapeutics from an “outperform” rating to a “hold” rating in a research report on Tuesday, January 23rd. Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $55.00 to $87.00 in a research report on Wednesday, January 24th. Standpoint Research reiterated a “hold” rating on shares of Juno Therapeutics in a research report on Wednesday, January 24th. Leerink Swann cut Juno Therapeutics from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $56.00 to $87.00 in a research report on Tuesday, January 23rd. Finally, Needham & Company LLC cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have issued a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and a consensus target price of $51.20.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.